WO2021154056A3 - Use of pseudogene for diagnosis of malignancy of glioma - Google Patents

Use of pseudogene for diagnosis of malignancy of glioma Download PDF

Info

Publication number
WO2021154056A3
WO2021154056A3 PCT/KR2021/001271 KR2021001271W WO2021154056A3 WO 2021154056 A3 WO2021154056 A3 WO 2021154056A3 KR 2021001271 W KR2021001271 W KR 2021001271W WO 2021154056 A3 WO2021154056 A3 WO 2021154056A3
Authority
WO
WIPO (PCT)
Prior art keywords
glioma
diagnosis
pseudogene
biomarker
grade
Prior art date
Application number
PCT/KR2021/001271
Other languages
French (fr)
Korean (ko)
Other versions
WO2021154056A2 (en
Inventor
곽규범
임재준
안주원
박영준
심정민
Original Assignee
차의과학대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 차의과학대학교 산학협력단 filed Critical 차의과학대학교 산학협력단
Publication of WO2021154056A2 publication Critical patent/WO2021154056A2/en
Publication of WO2021154056A3 publication Critical patent/WO2021154056A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a pseudogene biomarker for diagnosis and/or prognosis prediction of glioma, and provided are a composition for diagnosis and/or prognosis prediction of glioma comprising a formulation for detecting the biomarker, a kit for diagnosis and/or prognosis prediction of glioma comprising the composition, and a method for providing information required for diagnosis and/or prognosis prediction of glioma by using the biomarker. The pseudogene biomarker can clearly diagnose the grade of glioma as grade 2 to grade 4, and the prognosis can be predicted according to the difference in expression level, thereby enabling accurate diagnosis and/or prediction of the glioma.
PCT/KR2021/001271 2020-01-31 2021-02-01 Use of pseudogene for diagnosis of malignancy of glioma WO2021154056A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2020-0012227 2020-01-31
KR1020200012227A KR102325356B1 (en) 2020-01-31 2020-01-31 Composition for diagnosis of malignancy of glioma using pseudogenes and use thereof

Publications (2)

Publication Number Publication Date
WO2021154056A2 WO2021154056A2 (en) 2021-08-05
WO2021154056A3 true WO2021154056A3 (en) 2021-09-23

Family

ID=77079772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/001271 WO2021154056A2 (en) 2020-01-31 2021-02-01 Use of pseudogene for diagnosis of malignancy of glioma

Country Status (2)

Country Link
KR (1) KR102325356B1 (en)
WO (1) WO2021154056A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092995B2 (en) * 2009-01-02 2012-01-10 The Board Of Trustees Of The University Of Illinois Expressed pseudogene regulates gene expression
US20170101684A1 (en) * 2014-03-28 2017-04-13 Erasmus University Medical Center Rotterdam Method for diagnosing and treating multiple myeloma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092995B2 (en) * 2009-01-02 2012-01-10 The Board Of Trustees Of The University Of Illinois Expressed pseudogene regulates gene expression
US20170101684A1 (en) * 2014-03-28 2017-04-13 Erasmus University Medical Center Rotterdam Method for diagnosing and treating multiple myeloma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAI-MING GAO;XIN-CHENG CHEN;JUN-XIA ZHANG;YINGYI WANG;WEI YAN;YONG-PING YOU: "A pseudogene-signature in glioma predicts survival", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 34, no. 1, 4 March 2015 (2015-03-04), London UK, pages 23, XP021218356, ISSN: 1756-9966, DOI: 10.1186/s13046-015-0137-6 *
LIU BO, LIU JINGPING, LIU KUN, HUANG HAO, LI YEXIN, HU XIQI, WANG KE, CAO HUI, CHENG QUAN: "A prognostic signature of five pseudogenes for predicting lower-grade gliomas", BIOMEDICINE & PHARMACOTHERAPY, vol. 117, no. 109116, 1 September 2019 (2019-09-01), FR, pages 1 - 8, XP055851609, ISSN: 0753-3322, DOI: 10.1016/j.biopha.2019.109116 *
WANG YULIN, LIU XIN, GUAN GEFEI, XIAO ZHE, ZHAO WEIJIANG, ZHUANG MINGHUA: "Identification of a Five-Pseudogene Signature for Predicting Survival and Its ceRNA Network in Glioma", FRONTIERS IN ONCOLOGY, vol. 9, no. 1059, pages 1 - 14, XP055851628, DOI: 10.3389/fonc.2019.01059 *

Also Published As

Publication number Publication date
KR20210098262A (en) 2021-08-10
KR102325356B1 (en) 2021-11-11
WO2021154056A2 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
BR112012019542A2 (en) "method for assessing renal status in an individual, measuring one or more biomarkers, and, kit"
ATE548467T1 (en) METHOD FOR IDENTIFYING BIOMARKERS USEFUL IN DIAGNOSING BIOLOGICAL CONDITIONS
IN2013CN01129A (en)
BR112013033488B8 (en) METHODS TO FACILITATE THE DIAGNOSIS OF COGNITIVE IMPAIRMENT DUE TO ALZHEIMER DISEASE OR MILD COGNITIVE IMPAIRMENT (MCI) AND KIT
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
IL252832A0 (en) Use of biomarkers for detecting ovarian cancer
NZ592358A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
NZ620799A (en) Molecular diagnostic test for cancer
NZ591437A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010041892A3 (en) Novel application of aimp1 polypeptide
BR112012032537A2 (en) lung cancer biomarkers and their uses
WO2012008807A3 (en) Use of tgase2 and vhl as a diagnostic marker for renal cell carcinoma
WO2009006347A3 (en) Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
CA2850449C (en) Dynamic of sflt-1 or endoglin/pigf ratio as an indicator for imminent preeclampsia and/or hellp syndrome
WO2011154698A3 (en) Method,array and use thereof
ATE471512T1 (en) USE OF PROTEIN S100A 12 AS A MARKER FOR COLORECTAL CARCINOMA
CA2798126A1 (en) Test for male fertility
EA201290192A1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF KIDNEY DAMAGE AND RENAL FAILURE
MX2012003168A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure.
EP4299586A3 (en) Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
WO2020136505A3 (en) Compositions and methods for diagnosing and treating degenerative mitral valve disease in a canine
MY159867A (en) Detection and enumeration of microorganisms
WO2021154056A3 (en) Use of pseudogene for diagnosis of malignancy of glioma
DE602005013430D1 (en) USING ASC AS A MARKER FOR COLORECTAL CARCINOMAS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21746993

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21746993

Country of ref document: EP

Kind code of ref document: A2